Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vickerman

Showing results (221-230 of 397) with videos related to

Pageof 40
Sort By:
HIV Medicine|January 29, 2021
Modelling the impact of an HIV testing intervention on HIV transmission among men who have sex with men in ChinaRoss D Booton, Jason J Ong, Amy Lee, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
Trends in HIV incidence following scale-up of harm reduction interventions among people who inject drugs in Kachin, Myanmar, 2008-2020: analysis of a retrospective cohort datasetAnna L McNaughton, Jack Stone, Khine Thet Oo, et al.
Lancet (London, England)|October 29, 2019
Global patterns of opioid use and dependence: harms to populations, interventions, and future actionLouisa Degenhardt, Jason Grebely, Jack Stone, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 29, 2018
A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugsVivian D Hope, Ross J Harris, Peter Vickerman, et al.
Plos One|October 22, 2014
Community mobilisation and empowerment interventions as part of HIV prevention for female sex workers in Southern India: a cost-effectiveness analysisAnna Vassall, Sudhashree Chandrashekar, Michael Pickles, et al.
BMC Infectious Diseases|January 11, 2014
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product pricesFern Terris-Prestholt, Anna M Foss, Andrew P Cox, et al.
Hepatology (Baltimore, Md.)|February 12, 2016
Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysisNatasha K Martin, Peter Vickerman, Iain F Brew, et al.
AIDS (London, England)|January 29, 2014
Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South AfricaNatasha K Martin, Angela Devine, Jeffrey W Eaton, et al.
Plos One|July 29, 2014
Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and preventionLucas Wiessing, Marica Ferri, Bart Grady, et al.
Journal of Viral Hepatitis|March 12, 2026
Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, PakistanSabeen Shah, Nyashadzaishe Mafirakureva, Adam Trickey, et al.
Pageof 40

Showing results (221-230 of 397) with videos related to

Sort By:
Pageof 40
HIV Medicine|January 29, 2021
Modelling the impact of an HIV testing intervention on HIV transmission among men who have sex with men in ChinaRoss D Booton, Jason J Ong, Amy Lee, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
Trends in HIV incidence following scale-up of harm reduction interventions among people who inject drugs in Kachin, Myanmar, 2008-2020: analysis of a retrospective cohort datasetAnna L McNaughton, Jack Stone, Khine Thet Oo, et al.
Lancet (London, England)|October 29, 2019
Global patterns of opioid use and dependence: harms to populations, interventions, and future actionLouisa Degenhardt, Jason Grebely, Jack Stone, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 29, 2018
A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugsVivian D Hope, Ross J Harris, Peter Vickerman, et al.
Plos One|October 22, 2014
Community mobilisation and empowerment interventions as part of HIV prevention for female sex workers in Southern India: a cost-effectiveness analysisAnna Vassall, Sudhashree Chandrashekar, Michael Pickles, et al.
BMC Infectious Diseases|January 11, 2014
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product pricesFern Terris-Prestholt, Anna M Foss, Andrew P Cox, et al.
Hepatology (Baltimore, Md.)|February 12, 2016
Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysisNatasha K Martin, Peter Vickerman, Iain F Brew, et al.
AIDS (London, England)|January 29, 2014
Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South AfricaNatasha K Martin, Angela Devine, Jeffrey W Eaton, et al.
Plos One|July 29, 2014
Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and preventionLucas Wiessing, Marica Ferri, Bart Grady, et al.
Journal of Viral Hepatitis|March 12, 2026
Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, PakistanSabeen Shah, Nyashadzaishe Mafirakureva, Adam Trickey, et al.
Pageof 40